ArticleBlood advances2023

A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT.

Misha C Tran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.